Скачать или смотреть Interview with Pharma Equity Group's CEO Christian Tange

Analyst Group interview Pharma Equity Group's CEO Christian Tange in connection to the company's H1-report.

00:07 - For those unfamiliar with Pharma Equity Group (PEG), could you provide an overview of the business model and the markets you are addressing?

02:50 - You assumed the role of CEO on April 1, 2025. Could you share more about your background and the experiences you bring to lead PEG into its next phase?

03:48 - PEG’s portfolio company, Reponex, is currently prioritizing two of its six Phase II candidates, RNX-011 (peritonitis) and RNX-051 (colorectal cancer), as they have the clearest paths to commercialization. Could you elaborate on the near-term catalysts for these programs and update us on discussions with potential licensing partners?

05:07 - During Q2-25, you announced a transformative strategy to reposition as a diversified life science investment platform, broadening into Medical Devices and MedTech. How do you see these segments shaping PEG’s growth outlook, and in what ways do they enhance the balance of risk and return compared to the current pharma assets?

06:23 - With only DKK 0.7m in cash at the end of H1-25, how do you assess the current liquidity situation, and what should investors expect in terms of potential financing solutions to reinforce the balance sheet going forward?

07:40 - Looking ahead, what will be the key priorities for PEG in the remainder of 2025?

08:42 - In conclusion, could you highlight the main reasons why PEG is an attractive investment today?

Read more here: https://analystgroup.se/bolag/pharma-...